Compare · ABBV vs DNTH
ABBV vs DNTH
Side-by-side comparison of AbbVie Inc. (ABBV) and Dianthus Therapeutics Inc. (DNTH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and DNTH operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $449.63B, about 77.9x DNTH ($5.77B).
- Over the past year, ABBV is up 37.7% and DNTH is up 407.6% - DNTH leads by 369.9 points.
- ABBV has been more active in the news (13 items in the past 4 weeks vs 3 for DNTH).
- ABBV has more recent analyst coverage (25 ratings vs 14 for DNTH).
- Company
- AbbVie Inc.
- Dianthus Therapeutics Inc.
- Price
- $254.52+0.06%
- $105.38+10.55%
- Market cap
- $449.63B
- $5.77B
- 1M return
- +14.38%
- +33.54%
- 1Y return
- +37.70%
- +407.61%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- 2018
- News (4w)
- 13
- 3
- Recent ratings
- 25
- 14
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Latest ABBV
- Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
- SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
- SEC Form 4 filed by Director Rapp Edward J
- SEC Form 4 filed by Director Quaggin Susan E
- A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
- AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- FDA Approval for SKYRIZI issued to ABBVIE INC
Latest DNTH
- EVP, CFO & CBO Savitz Ryan exercised 31,249 shares at a strike of $21.77 and sold $3,157,151 worth of shares (31,249 units at $101.03) as part of a pre-agreed trading plan (SEC Form 4)
- Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4)
- Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis
- SVP, General Counsel and Sec. Veness Adam M exercised 30,000 shares at a strike of $17.88 and sold $2,423,958 worth of shares (30,000 units at $80.80) as part of a pre-agreed trading plan (SEC Form 4)
- Dianthus Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- EVP, Head of R&D Randhawa Simrat exercised 26,530 shares at a strike of $18.85 and sold $2,404,077 worth of shares (26,530 units at $90.62) as part of a pre-agreed trading plan (SEC Form 4)
- Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Dianthus Therapeutics to Participate in Two Investor Conferences
- SEC Form 4 filed by Director Lawton Alison Frances
- SEC Form 4 filed by Director Romano Steven J.